Testing a new narcolepsy drug for excessive daytime sleepiness
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with narcolepsy type 1 or type 2 in the last 10 years.
- You have excessive daytime sleepiness.
- Any other medicines you take for sleepiness or mood must be at the same dose for at least 3 months before the study starts and stay stable during the study.
- You cannot use as-needed medicines (like stimulants or modafinil) that affect daytime sleepiness.
- You do not have serious liver, kidney, or heart problems (like long QT syndrome).
- You do not have a history of bipolar disorder or psychosis, and any depression must be well-controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication called samelisant can reduce extreme daytime sleepiness and sudden muscle weakness (cataplexy) in people with narcolepsy. If it works, it could offer a new treatment option for managing this sleep disorder.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
This study follows people with frequent daytime sleepiness (sometimes from narcolepsy or hypersomnia) and compares them with matched healthy people, including some with sleep apnea. The goal is to better understand what causes sleepiness and to improve how these conditions are recognized and measured.
This study tests whether a new medication called Lu AH69593 is safe and well-tolerated in healthy adults and people with narcolepsy type 1. Researchers want to understand how the drug affects the body and whether it could help treat excessive daytime sleepiness.
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
Hear when a new Fatigue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.